Publications

Comella, C, RA Hauser, SH Isaacson, D Truong, O Oguh, J Hui, ES Molho, et al. 2022. “Efficacy and Safety of Two IncobotulinumtoxinA Injection Intervals in Cervical Dystonia Patients With Inadequate Benefit from Standard Injection Intervals of Botulinum Toxin: Phase 4, Open-Label, Randomized, Noninferiority Study. 2022 Mar 14;”. Clin Park Relat Disord.

Hauser, RA, J Lytle, AE Formella, and CM Tanner. 2022. “Amantadine Delayed Release/Extended Release Capsules Significantly Reduce OFF Time in Parkinson’s Disease. 2022 Mar 18;8(1):29. Doi: 10.1038/S41531-022-00291-1. PMID: 35304480.”. NP J Parkinsons Dis.

Hauser, RA, H Barkay, A Wilhelm, M Wieman, JM Savola, and MF Gordon. 2022. “Minimal Clinically Important Change in Abnormal Involuntary Movement Scale Score in Tardive Dyskinesia As Assessed in Pivotal Trials of Deutetrabenazine. 2022 Mar 2;97:47-51. Doi: 10.1016. Epub 2022 Mar 2.PMID: 35299070.”. Parkinsonism Relat Disord.

Hauser, RA, H Barkway, HH Fernandez, SA Factor, J Jimenez-Shahed, N Gross, L Marinelli, et al. 2022. “Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. Doi: 10.3389/Fneur.2022.773999. ECollection 2022. PMID: 35280262.”. Front Neurol.

Hauser, RA, N Giladi, W Poewe, J Brotchie, H Friedman, S Oren, and P Litman. 2022. “P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. Doi: 10.1007/S12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.”. Adv. Ther.

Hauser, RA, A Favit, LA Hewitt, A Lindsten, S Gomy, S Kymes, and SH Isaacson. 2022. “Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. Doi: 10.1007/S40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.”. Neurol Ther.

Lew, MF, RA Hauser, SH Isaacson, D Truong, AT Patel, A Brashear, W Ondo, et al. 2021. “AbobotulinumtoxinA Provides Flexibility for the Treatment of Cervical Dystonia With 500 U/1 mL and 500 U/2 mL Dilutions. 5:100115. Doi: 10.1016/J.prdoa.2021.100115. ECollection 2021. PMID: 34888518.”. Clin Park Relat Disord.

Pringsheim, T, GS Day, DB Smith, A Rae-Grant, N Licking, MJ Armstrong, RMA de Brie, et al. 2021. “Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-957. Doi: 10.1212/WNL.0000000000012868. PMID: 34782410.”. Neurology.

Hauser, RA, Parkinsons Study Group SURE-PD3 Investigators, and . 2021. “Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. Doi: 0.1001/Jama.2021.10207. PMID: 34519802.”. JAMA.

Hauser, RA, N Hattori, H Fernandez, SH Isaacson, H Mochizuki, O Rascol, F Stocchi, et al. 2021. “Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, As Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675. Doi: 10.3233/JPD-212672. PMID: 34486986”. J Parkinsons Dis.